Efalizumab (Raptiva™): Historical Information and Mechanism of Action
Efalizumab (marketed as Raptiva™) is no longer available, having been withdrawn from the market in 2009. Therefore, the information presented below is for historical purposes only.
Efalizumab belonged to the class of biologic response modifiers known as T-cell blockers. T-cell. This drug proved to be an effective treatment for patients suffering from plaque moderate to severe plaque psoriasis.
Efalizumab Mechanism of Action
Efalizumab was essentially a protein genetically modified murine protein designed to inhibit T-cell activation and proliferation A biopsy T-cell. proliferation. It achieved this by binding to the CD11a receptors expressed on the surface of these cells. By blocking this interaction, T-cells were prevented from releasing cytokines, cytokines, which are the primary cause of primary Lesions of the inflammation, inflammation, redness, itching, and the scaly plaques characteristic of psoriasis.
Administration and Dosing Regimens
Initial studies of efalizumab involved intravenous (IV) administration. However, a subcutaneous (SC) formulation was later developed and used. formulation. subcutaneous (SC). A weekly dosing regimen over a 12-week period managed to improve the psoriasis condition in approximately 50% of treated patients.
Improvements observed after completing the initial 12 weeks of treatment could be maintained by continuing with weekly injection appointments or adjusting the frequency to a dose every two weeks.
Reported Side Effects
Generally, efalizumab was well tolerated by patients. The most commonly reported side effects included headache, nausea, chills, generalized pain, fever, palmar erythema secondary nonspecific infection, similar to the common cold. These symptoms tended to manifest more frequently after the first injection and tended to decrease with subsequent doses.
Serious Risks Associated with Treatment
Since efalizumab acted as an immunosuppressive agent, it inevitably increased the patient's susceptibility susceptibility to developing infections. Unlike other.
KEY WARNING: On April 9, 2009, Genentech made the decision to voluntarily withdraw efalizumab (Raptiva) from the U.S. market due to a potentially elevated risk of chronic, progressive multifocal leukoencephalopathy (PML). This withdrawal followed the safety alert issued on February 19, 2009, by the FDA's Center for Drug Evaluation and Research, after reports of four patients treated with this medication who developed this rare, potentially fatal brain infection, and other serious infections.
The official source of information for these prescription medications, including their approved uses and risk details, is found in the data sheets approved by New Zealand. It is recommended to consult the specific New Zealand technical sheet on the Medsafe website for reference.
Due to these serious risks, efalizumab ceased to be part of the therapeutic arsenal for the treatment of psoriasis.
